32,109 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Acquired by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC purchased a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 32,109 shares of the life sciences company's stock, valued at approximately $728,000.

Other hedge funds have also bought and sold shares of the company. Nisa Investment Advisors LLC boosted its stake in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Empowered Funds LLC purchased a new position in Integra LifeSciences in the fourth quarter valued at approximately $180,000. Centiva Capital LP bought a new position in Integra LifeSciences during the third quarter valued at $192,000. Mitsubishi UFJ Asset Management UK Ltd. bought a new position in Integra LifeSciences during the fourth quarter valued at $204,000. Finally, Romano Brothers AND Company purchased a new stake in Integra LifeSciences in the fourth quarter worth $204,000. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Price Performance

Shares of IART traded down $0.43 during midday trading on Friday, hitting $16.99. 659,615 shares of the company traded hands, compared to its average volume of 1,049,936. Integra LifeSciences Holdings Co. has a one year low of $15.97 and a one year high of $33.04. The firm has a market cap of $1.31 billion, a P/E ratio of -188.76, a PEG ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The stock has a 50-day moving average of $22.28 and a 200-day moving average of $22.31.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The business had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. During the same quarter in the prior year, the firm posted $0.89 EPS. Integra LifeSciences's revenue was up 11.5% on a year-over-year basis. As a group, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Truist Financial dropped their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $22.71.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.